polycystic ovarian syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: 5 grams of Psyllium twice daily for 2 month. Intervention 2: control group: 5 grams of Microcrystalline cellulose as a placebo, twice daily for 2 month.
Placebo
Intervention group: 5 grams of Psyllium twice daily for 2 month
control group: 5 grams of Microcrystalline cellulose as a placebo, twice daily for 2 month
Sponsors
Vice chancellor for research, Urmia University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age range 18-45 years; PCOs diagnosis based on the Rotterdam; Persons with fasting glucose concentrations in the range of less than 126 mg /dl; Exclusion criteria: Smoker or addict; Individuals receiving glucose-lowering drugs other than Metformin; Corticosteroid consumer; Consumer drugs such as Lithium, Carbamazepine and Digoxin; Warfarin consumer; Individuals with a history of Myocardial Infarction, Kidney, Liver and Lung diseases; Individuals with Thyroid Dysfunction; Individuals with major surgery in the last 6 months; Individuals with a history of allergy to Psyllium and Aspartame; Patients with Phenylketonuria; Patients with type 1 diabetes, Gastrectomy and Parkinson's disease; Individuals with a history of Gastrointestinal Disease, particularly persistent constipation and narrowing and blockage of the intestinal tract; Individuals treated with drugs that affect blood lipid profile; Individuals with a history of diseases such as Congenital Adrenal Hyperplasia, Cushing's syndrome, Hyperprolactinemia, the androgen-secreting tumors and Thyroid disease; Patients treated with antidepressant medications and recent treatment for eating disorder; Individuals treated with other fiber supplements.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose (FBS). Timepoint: before intervention, 2 month after intervention. Method of measurement: mg/dl.;Fasting serum insulin. Timepoint: before intervention, 2 month after intervention. Method of measurement: µU/mL.;Triglyceride. Timepoint: before intervention, 2 month after intervention. Method of measurement: mg/dl.;Total Cholesterol. Timepoint: before intervention, 2 month after intervention. Method of measurement: mg/dl.;LDL-C. Timepoint: before intervention, 2 month after intervention. Method of measurement: mg/dl.;HDL-C. Timepoint: before intervention, 2 month after intervention. Method of measurement: mg/dl.;Homeostasis model assessment of insulin resistance (HOMA-IR). Timepoint: before intervention, 2 month after intervention. Method of measurement: FBS*insulin/22.5. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fat mass. Timepoint: before intervention, 2 month after intervention. Method of measurement: gr.;Body Mass Index (BMI). Timepoint: before intervention, 2 month after intervention. Method of measurement: kg/m2.;Fat Free Mass. Timepoint: before intervention, 2 month after intervention. Method of measurement: gr.;Waist to hip ratio (WHR). Timepoint: before intervention, 2 month after intervention. Method of measurement: waist/hip.;Number and regularity of menstrual cycle. Timepoint: before intervention, 2 month after intervention. Method of measurement: Ask a Question. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Rasoul Zarrin
Urmia University of Medical Sciences
Outcome results
None listed